Katie Mc Ginn
About Katie Mc Ginn
Katie Mc Ginn is the Director of Quality Assurance at both Bristol Myers Squibb and Mirati Therapeutics, with over 20 years of experience in the pharmaceutical industry.
Title and Current Positions
Katie Mc Ginn is currently serving as the Director of Quality Assurance at both Bristol Myers Squibb and Mirati Therapeutics. She manages her responsibilities remotely from Delaware for Bristol Myers Squibb and from San Diego, California for Mirati Therapeutics.
Previous Experience at Incyte
Katie Mc Ginn worked at Incyte for a total of six years in various roles. From 2019 to 2022, she served as Director. Before that, she held the position of Associate Director from 2016 to 2019. Initially, she joined Incyte as Quality Control Senior Manager from 2015 to 2016.
Career Beginnings in Analytical Chemistry
Katie Mc Ginn began her career in analytical chemistry, working at Merck & Co. as a Senior Analytical Chemist from 1996 to 2004. She then moved to Cephalon, Inc, where she served as an Analytical Chemist from 2004 to 2011, further honing her expertise.
Education and Chemistry Expertise
Katie Mc Ginn holds a Bachelor of Science degree in Chemistry from The College of New Jersey, where she studied from 1992 to 1996. Her academic background laid the groundwork for her extensive career in the pharmaceutical industry.
Key Roles in Regulatory Approvals and Acquisitions
Katie Mc Ginn has played critical roles in quality control and assurance projects that led to regulatory approvals for new pharmaceutical products. Notably, she contributed to the quality assurance processes during the acquisition of Mirati Therapeutics by Bristol Myers Squibb in January 2024.